KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Current Taxes: 2017-2020

Historic Current Taxes for Aquestive Therapeutics (AQST) over the last 2 years, with Dec 2020 value amounting to $316,000.

  • Aquestive Therapeutics' Current Taxes rose 5.33% to $316,000 in Q4 2020 from the same period last year, while for Dec 2020 it was $316,000, marking a year-over-year increase of 5.33%. This contributed to the annual value of $316,000 for FY2020, which is 5.33% up from last year.
  • According to the latest figures from Q4 2020, Aquestive Therapeutics' Current Taxes is $316,000, which was down 14.59% from $370,000 recorded in Q1 2020.
  • Aquestive Therapeutics' 5-year Current Taxes high stood at $388,000 for Q4 2018, and its period low was $176,000 during Q2 2019.
  • Moreover, its 3-year median value for Current Taxes was $316,000 (2020), whereas its average is $305,889.
  • As far as peak fluctuations go, Aquestive Therapeutics' Current Taxes crashed by 33.08% in 2019, and later increased by 5.33% in 2020.
  • Over the past 4 years, Aquestive Therapeutics' Current Taxes (Quarterly) stood at $372,000 in 2017, then rose by 4.30% to $388,000 in 2018, then decreased by 22.68% to $300,000 in 2019, then rose by 5.33% to $316,000 in 2020.
  • Its last three reported values are $316,000 in Q4 2020, $370,000 for Q1 2020, and $300,000 during Q4 2019.